Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 335

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Open access
de Groot, Stefanie, Lugtenberg, Rieneke T., Cohen, Danielle, Welters, Marij J. P., Ehsan, Ilina, Vreeswijk, Maaike P. G., Smit, Vincent T. H. B. M., de Graaf, Hiltje, Heijns, Joan B., Portielje, Johanneke E. A., van de Wouw, Agnes J., Imholz, Alex L. T., Kessels, Lonneke W., Vrijaldenhoven, Suzan, Baars, Arnold, Kranenbarg, Elma Meershoek-Klein, Carpentier, Marjolijn Duijm-de, Putter, Hein, van der Hoeven, Jacobus J. M., Nortier, Johan W. R., Longo, Valter D., Pijl, Hanno, Kroep, Judith R., Dutch Breast Cancer Research Group (BOOG), de Graaf, Hiltje, Heijns, Joan B., Portielje, Johanneke E. A., van de Wouw, Agnes J., Imholz, Alex L. T., Kessels, Lonneke W., Vrijaldenhoven, Suzan, Baars, Arnold, Göker, Emine, Pas, Anke J. M., Honkoop, Aafke H., van Leeuwen-Stok, A. Elise, Kroep, Judith R.·2020·Nature Communications

Abstract

Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative stage II/III breast cancer, without diabetes and a BMI over 18 kg m−2, to receive either a fasting mimicking diet (FMD) or their regular diet for 3 days prior to and during neoadjuvant chemotherapy. Here we show that there was no difference in toxicity between both groups, despite the fact that dexamethasone was omitted in the FMD group. A radiologically complete or partial response occurs more often in patients using the FMD (OR 3.168, P = 0.039). Moreover, per-protocol analysis reveals that the Miller&Payne 4/5 pathological response, indicating 90–100% tumor-cell loss, is more likely to occur in patients using the FMD (OR 4.109, P = 0.016). Also, the FMD significantly curtails chemotherapy-induced DNA damage in T-lymphocytes. These positive findings encourage further exploration of the benefits of fasting/FMD in cancer therapy. Trial number: NCT02126449.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-16138-3

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 335

Metadata

Authors
de Groot, S., Lugtenberg, R. T., Cohen, D., Welters, M. J. P., Ehsan, I., Vreeswijk, M. P. G., Smit, V. T. H. B. M., de Graaf, H., Heijns, J. B., Portielje, J. E. A., van de Wouw, A. J., Imholz, A. L. T., Kessels, L. W., Vrijaldenhoven, S., Baars, A., Kranenbarg, E. M.-K., Carpentier, M. D.-D., Putter, H., van der Hoeven, J. J. M., Nortier, J. W. R., Longo, V. D., Pijl, H., Kroep, J. R., Dutch Breast Cancer Research Group (BOOG), de Graaf, H., Heijns, J. B., Portielje, J. E. A., van de Wouw, A. J., Imholz, A. L. T., Kessels, L. W., Vrijaldenhoven, S., Baars, A., Göker, E., Pas, A. J. M., Honkoop, A. H., van Leeuwen-Stok, A. E., & Kroep, J. R.
Venue
Nature Communications
Published
2020-06-23
Volume
11
Issue
1
Pages
3083-3083
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3036980661
Cited by
335
References
7
FWCI
24.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. https://app.cochat.ai/papers/10.1038/s41467-020-16138-3
The paper
de Groot, S., Lugtenberg, R. T., Cohen, D., Welters, M. J. P., Ehsan, I., Vreeswijk, M. P. G., Smit, V. T. H. B. M., de Graaf, H., Heijns, J. B., Portielje, J. E. A., van de Wouw, A. J., Imholz, A. L. T., Kessels, L. W., Vrijaldenhoven, S., Baars, A., Kranenbarg, E. M.-K., Carpentier, M. D.-D., Putter, H., van der Hoeven, J. J. M., . . . Kroep, J. R. (2020). Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications. https://doi.org/10.1038/s41467-020-16138-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.